Emergent BioSolutions stock jumps 19.6% on biodefense demand and strong earnings

Emergent BioSolutions shares surged nearly 19.6% to $7.57 in midday trading, driven by investor interest in biodefense stocks following a suspected pneumonic plague death at a Russian research institute in Siberia. The U.S. State Department, led by Secretary Marco Rubio, is monitoring the incident and coordinating with the CDC, urging Moscow to share timely information. The company also reported strong quarterly results, with adjusted EPS of $0.60 versus an expected loss of $0.08, and revenue of $234.3 million exceeding forecasts. Analysts maintain a "Hold" rating with a $10.00 average price target, while the stock remains about 49% down year-to-date. The company has reduced total debt to $515 million through refinancing and bond buybacks.